Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.
Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.
StrongSupportsmedium confidence
Major cardiovascular outcome trials have demonstrated significant reductions in major adverse cardiovascular events and, to a lesser degree, non-fatal stroke among patients receiving GLP-1RAs.
Why this rating
Based on major cardiovascular outcome trials mentioned in the abstract.
Source
Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review
Shayan Khan et al. · Biomedicines · 2026
DOI 10.3390/biomedicines14040743
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →